Anlon Healthcare Limited (AHCL) Q2 FY27 Financial Results: PAT ₹8.28 & Revenue ₹87.62

Investor Takeaways

Overall Tone: Positive

Key Financial Highlights

What Changed

Anlon Healthcare Limited reported consolidated revenue of ₹87.62 Crore for Q1FY27, reflecting a 163.02% year-on-year increase. EBITDA grew 150.14% to ₹15.65 Crore, and net profit rose 133.13% to ₹8.28 Crore compared to the same quarter last year. The company completed the acquisition of Remember India Health Links Pvt. Ltd. for ₹5.38 Crore, securing a 63.98% stake and entering the finished dosage formulations segment. This strategic move supports the management’s vision of building an integrated pharmaceutical platform. The filing indicates confidence in sustaining a 30% compound annual growth rate (CAGR) over the next three years while maintaining EBITDA margins within the 25%-30% range. The acquisition is expected to drive operational synergies and expand the company’s product portfolio and market reach.

Peer Comparison

Anlon Healthcare’s valuation multiples and profitability ratios are not currently available for direct comparison. However, its peers exhibit varying P/E ratios and strong ROE/ROCE profiles, with higher market capitalizations indicating larger scale operations.

Risks & Concerns

Quarterly Trend

The company’s revenue and profitability trends show growth momentum, with Q4FY26 reporting revenue of ₹50.89 Crore and net profit of ₹11.07 Crore, reflecting an operating profit margin of 30.05%. This performance contributed to the strong Q1FY27 results.

📄 View Original Announcement (PDF)

About Anlon Healthcare Limited (AHCL)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

View full AHCL stock details →